Neuraptive Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neuraptive Therapeutics, Inc.
Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter.
- Drug Delivery
- Consumables, Central Supplies
- Surgical Equipment & Devices